Making Indigenous Peoples Equal Partners in Gene Research
By Ed Yong,
The Atlantic
| 10. 23. 2015
Untitled Document
The Akimel O’odham (Pima), a group of Native Americans from Arizona, have one of the highest rates of type 2 diabetes in the world. More than half the adults are affected, and while diet and lifestyle factors certainly contribute, scientists have long suspected that the community carries genetic variants that also affect their risk.
Since 1965, the tribe have been intensely studied by researchers from the National Institutes of Health. This work has been a boon to the outside world: It was instrumental in clarifying the heritable nature of type 2 diabetes, and its connection with obesity. But for most of that time, the Akimel O’odham have been passive participants in the research of their lives.
The NIH had promised to fund research and develop services that would improve the health of the community. But preventative studies only started in the 1990s, some three decades in, and health programs were small and delivered through the existing Indian Health Service. Meanwhile, a significant amount of money went into studying type 1 diabetes—a disease that mostly affects people...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...